Predictive value of CD19 measurements for bacterial infections in children infected with human immunodeficiency virus. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Predictive value of CD19 measurements for bacterial infections in children infected with human immunodeficiency virus.

Clin Diagn Lab Immunol. 1999 Mar;6(2):247-53. Unique Identifier : AIDSLINE MED/99167673
Betensky RA; Calvelli T; Pahwa S; Department of Biostatistics, Harvard School of Public Health,; Boston, Massachusetts 02115, USA. betensky@hsph.harvard.edu


Abstract: We investigated the predictive value of CD19 cell percentages (CD19%) for times to bacterial infections, using data from six pediatric AIDS Clinical Trials Group protocols and adjusting for other potentially prognostic variables, such as CD4%, CD8%, immunoglobulin (IgA) level, lymphocyte count, prior infections, prior zidovudine treatment, and age. In addition, we explored the combined effects of CD19% and IgG level in predicting time to infection. We found that a low CD19% is associated with a nonsignificant 1.2-fold increase in hazard of bacterial infection (95% confidence interval: 0.97, 1.49). In contrast, a high IgG level is associated with a nonsignificant 0.87-fold decrease in hazard of infection (95% confidence interval: 0.68, 1.12). CD4% was more prognostic of time to bacterial infection than CD19% or IgG level. Low CD19% and high IgG levels together lead to a significant (P < 0. 01) 0.50-fold decrease in hazard (95% confidence interval: 0.35, 0. 73) relative to low CD19% and low IgG levels. Similarly, in a model involving assay result changes (from baseline to 6 months) as well as baseline values, the effect of CD19% by itself is reversed from its effect in conjunction with IgG. In this model, CD19% that are increasing and high are associated with decreases in hazard of infection (P < 0.01), while increasing CD19% and increasing IgG levels are associated with significant (at the P = 0.01 level) fourfold increases in hazard of infection relative to stable CD19% and decreasing, stable, or increasing IgG levels. Our data suggest that CD19%, in conjunction with IgG level, provides a useful prognostic tool for bacterial infections. It is highly likely that T-helper function impacts on B-cell function; thus, inclusion of CD4% in such analyses may greatly enhance the assessment of risk for bacterial infection.
Keywords: JOURNAL ARTICLE Adolescence Antibodies, Bacterial/BLOOD Antigens, CD19/*BLOOD AIDS-Related Opportunistic Infections/*DIAGNOSIS/IMMUNOLOGY B-Lymphocytes/CYTOLOGY/MICROBIOLOGY/VIROLOGY Bacterial Infections/*DIAGNOSIS/IMMUNOLOGY/*VIROLOGY Child Child, Preschool Female Human IgA/BLOOD IgG/BLOOD Immunophenotyping Infant Infant, Newborn Lymphocyte Count Male Predictive Value of Tests Receptors, IgE/BLOOD Support, U.S. Gov't, P.H.S. Time FactorsKWDjournalarticleadolescenceantibodies,bacterial/bloodantigens,cd19/KWDbloodaids-relatedopportunisticinfections/KWDdiagnosis/immunologyb-lymphocytes/cytology/microbiology/virologybacterialinfections/KWDdiagnosis/immunology/KWDvirologychildchild,preschoolfemalehumaniga/bloodigg/bloodimmunophenotypinginfantinfant,newbornlymphocytecountmalepredictivevalueoftestsreceptors,ige/bloodsupport,uKWDsKWDgov't,pKWDhKWDsKWDtimefactors
990630
A9960962

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .